CN116917284A - O-糖蛋白-2-乙酰胺基-2-脱氧-3-d-吡喃葡萄糖苷酶抑制剂的结晶形式 - Google Patents

O-糖蛋白-2-乙酰胺基-2-脱氧-3-d-吡喃葡萄糖苷酶抑制剂的结晶形式 Download PDF

Info

Publication number
CN116917284A
CN116917284A CN202180066901.9A CN202180066901A CN116917284A CN 116917284 A CN116917284 A CN 116917284A CN 202180066901 A CN202180066901 A CN 202180066901A CN 116917284 A CN116917284 A CN 116917284A
Authority
CN
China
Prior art keywords
crystalline
compound
anhydrous
powder diffraction
diffraction pattern
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CN202180066901.9A
Other languages
English (en)
Chinese (zh)
Inventor
A·韦尔迪布
T·K·科雷亚
A·D·詹金斯
Y·林
C·李
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Bojian Massachusetts Co ltd
Original Assignee
Bojian Massachusetts Co ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Bojian Massachusetts Co ltd filed Critical Bojian Massachusetts Co ltd
Publication of CN116917284A publication Critical patent/CN116917284A/zh
Pending legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B2200/00—Indexing scheme relating to specific properties of organic compounds
    • C07B2200/13—Crystalline forms, e.g. polymorphs

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Psychiatry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Hospice & Palliative Care (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Saccharide Compounds (AREA)
CN202180066901.9A 2020-08-03 2021-08-03 O-糖蛋白-2-乙酰胺基-2-脱氧-3-d-吡喃葡萄糖苷酶抑制剂的结晶形式 Pending CN116917284A (zh)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US202063060281P 2020-08-03 2020-08-03
US63/060,281 2020-08-03
PCT/US2021/044341 WO2022031701A1 (en) 2020-08-03 2021-08-03 Crystaline forms of an o-glycoprotein-2-acetamido-2-deoxy-3-d-glucopyranosidase inhibitor

Publications (1)

Publication Number Publication Date
CN116917284A true CN116917284A (zh) 2023-10-20

Family

ID=77640732

Family Applications (1)

Application Number Title Priority Date Filing Date
CN202180066901.9A Pending CN116917284A (zh) 2020-08-03 2021-08-03 O-糖蛋白-2-乙酰胺基-2-脱氧-3-d-吡喃葡萄糖苷酶抑制剂的结晶形式

Country Status (18)

Country Link
US (1) US20230286972A1 (https=)
EP (1) EP4188925A1 (https=)
JP (1) JP7789056B2 (https=)
KR (1) KR20230061395A (https=)
CN (1) CN116917284A (https=)
AR (1) AR123132A1 (https=)
AU (1) AU2021322186A1 (https=)
BR (1) BR112023002013A2 (https=)
CA (1) CA3188250A1 (https=)
CL (1) CL2023000327A1 (https=)
CO (1) CO2023002543A2 (https=)
CR (1) CR20230118A (https=)
IL (1) IL300365A (https=)
MX (1) MX2023001469A (https=)
PE (1) PE20231168A1 (https=)
TW (1) TW202220984A (https=)
UY (1) UY39366A (https=)
WO (1) WO2022031701A1 (https=)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB2602139B (en) * 2020-12-18 2024-07-24 Nexeon Ltd Electroactive materials for metal-ion batteries
WO2025184490A1 (en) 2024-03-01 2025-09-04 Biogen Ma Inc. N-[4-fluor-5-[[(2s, 4 r)-4-[(6-methoxy-4-pyrimidinyl)oxy]- 2-methyl-1-pyrrolidinyl] methyl ]-2-thiazolyl]acetamid for use in the treatment of alzheimer disease

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2020061150A1 (en) * 2018-09-19 2020-03-26 Biogen Ma Inc. O-glycoprotein-2-acetamido-2-deoxy-3-d-glucopyranosidase inhibitors

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2780014A4 (en) 2011-11-18 2015-07-01 Constellation Pharmaceuticals Inc MODULATORS OF METHYL MODIFYING ENZYMES, COMPOSITIONS AND USES THEREOF
US9051269B2 (en) 2011-11-18 2015-06-09 Constellation Pharmaceuticals, Inc. Modulators of methyl modifying enzymes, compositions and uses thereof
WO2013078320A1 (en) 2011-11-21 2013-05-30 Constellation Pharmaceuticals Modulators of methyl modifying enzymes, compositions and uses thereof
JP5989805B2 (ja) 2012-02-10 2016-09-07 コンステレーション・ファーマシューティカルズ・インコーポレイテッドＣｏｎｓｔｅｌｌａｔｉｏｎ Ｐｈａｒｍａｃｅｕｔｉｃａｌｓ，Ｉｎｃ． メチル基変更酵素の調節物質、組成物及びその使用
MA38341B1 (fr) 2013-02-11 2018-11-30 Constellation Pharmaceuticals Inc Modulateurs d'enzymes de modification par méthylation, compositions et utilisations associées
US9745305B2 (en) 2013-03-15 2017-08-29 Constellation Pharmaceuticals, Inc. Modulators of methyl modifying enzymes, compositions and uses thereof
US9969716B2 (en) 2013-08-15 2018-05-15 Constellation Pharmaceuticals, Inc. Indole derivatives as modulators of methyl modifying enzymes, compositions and uses thereof
EP3555087A1 (en) 2016-12-16 2019-10-23 Janssen Pharmaceutica NV Monocyclic oga inhibitor compounds
TWI654978B (zh) 2017-01-27 2019-04-01 美商美國禮來大藥廠 5－甲基－1,2,4－二唑－3－基化合物
WO2018154133A1 (en) 2017-02-27 2018-08-30 Janssen Pharmaceutica Nv [1,2,4]-triazolo [1,5-a]-pyrimidinyl derivatives substituted with piperidine, morpholine or piperazine as oga inhibitors

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2020061150A1 (en) * 2018-09-19 2020-03-26 Biogen Ma Inc. O-glycoprotein-2-acetamido-2-deoxy-3-d-glucopyranosidase inhibitors

Also Published As

Publication number Publication date
TW202220984A (zh) 2022-06-01
PE20231168A1 (es) 2023-07-26
US20230286972A1 (en) 2023-09-14
AU2021322186A1 (en) 2023-04-06
BR112023002013A2 (pt) 2023-05-02
MX2023001469A (es) 2023-06-16
EP4188925A1 (en) 2023-06-07
CR20230118A (es) 2023-06-02
CA3188250A1 (en) 2022-02-10
CO2023002543A2 (es) 2023-06-09
JP7789056B2 (ja) 2025-12-19
UY39366A (es) 2022-02-25
CL2023000327A1 (es) 2023-10-06
JP2023536911A (ja) 2023-08-30
IL300365A (en) 2023-04-01
WO2022031701A1 (en) 2022-02-10
AR123132A1 (es) 2022-11-02
KR20230061395A (ko) 2023-05-08
WO2022031701A9 (en) 2022-03-31

Similar Documents

Publication Publication Date Title
US10081625B2 (en) 5-methyl-1,2,4-oxadiazol-3-yl compounds
EP1912973B1 (en) Crystalline forms of 4-methyl-n-[3-(4-methyl-imidazol-1-yl)-5-trifluoromethyl-phenyl]3-(4-pyridin-3-yl-pyrimidin-2-ylamino)-benzamide
US20220144778A1 (en) Mono-(acid) salts of 6-aminoisoquinolines and uses thereof
JP5635181B2 (ja) ニトロイミダゾール系化合物、その製造方法および用途
CN116917284A (zh) O-糖蛋白-2-乙酰胺基-2-脱氧-3-d-吡喃葡萄糖苷酶抑制剂的结晶形式
EA049044B1 (ru) Кристаллические формы ингибитора о-гликопротеин-2-ацетамидо-2-дезокси-3-d-глюкопиранозидазы
US11999726B2 (en) 5-methyl-4-fluoro-thiazol-2-yl compounds
HK40111611A (zh) 含氮并环类衍生物抑制剂的酸式盐或晶型及其制备方法和应用
HK40111611B (zh) 含氮并环类衍生物抑制剂的酸式盐或晶型及其制备方法和应用
CN121358724A (zh) 一种哌啶基吲哚化合物的盐及其制备方法
NZ754849B2 (en) N-[4-fluoro-5-[[(2s,4s)-2-methyl-4-[(5-methyl-1,2,4-oxadiazol-3-yl)methoxy]-1-piperidyl]methyl]thiazol-2-yl]acetamide as oga inhibitor

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination